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ABSTRACT
Background. Despite early referral of uraemic patients to nephrological care, suboptimal dialysis initiation (SDI) remains a
common problem associated with increased morbimortality. We hypothesized that SDI is related to pre-dialysis care.
Methods. In the ‘Peridialysis’ study, time and reasons for dialysis initiation (DI), clinical and biochemical data and centre
characteristics were registered during the pre- and peri-dialytic period for 1583 end-stage kidney disease patients starting
dialysis over a 3-year period at 15 nephrology departments in the Nordic and Baltic countries to identify factors associated
with SDI.
Results. SDI occurred in 42%. Risk factors for SDI were late referral, cachexia, comorbidity (particularly cardiovascular),
hypoalbuminaemia and rapid uraemia progression. Patients with polycystic renal disease had a lower incidence of SDI.
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High urea and C-reactive protein levels, acidosis and other electrolyte disorders were markers of SDI, independently of
estimated glomerular filtration rate (eGFR). SDI patients had higher eGFR than non-SDI patients during the pre-dialysis
period, but lower eGFR at DI. eGFR as such did not predict SDI. Patients with comorbidities had higher eGFR at DI. Centre
practice and policy did not associate with the incidence of SDI.
Conclusions. SDI occurred in 42% of all DIs. SDI was associated with hypoalbuminaemia, comorbidity and rate of eGFR loss,
but not with the degree of renal failure as assessed by eGFR.
Keywords: chronic kidney disease, dialysis, glomerular filtration rate, pre-dialysis care, unplanned dialysis
INTRODUCTION
Optimal timing of dialysis initiation (DI) in patients with end-
stage kidney disease (ESRD) is important for reducing the risk of
increased morbimortality due to uraemic complications.
Suboptimal dialysis initiations (SDIs)—using a temporary cen-
tral dialysis catheter access for haemodialysis (HD) or peritoneal
dialysis (PD) immediately after placement of a PD catheter—are
common, involving as many as 40–50% of ESRD patients starting
dialysis [1, 2], even in the absence of late referral to Nephrology
care [3]. SDI is associated with increased need for hospitaliza-
tions [4–6], increased early mortality after DI [5–8], lower quality
of life [9, 10] and high socioeconomic costs [1, 5]. Use of central
dialysis catheters for HD is associated with markedly increased
risk for fatal infections and cardiovascular mortality [11–15].
However, despite the awareness that SDI represents a major
problem, there are relatively few studies on the causes of SDI,
and previous studies on SDI have either been registry studies, or
generally characterized by low patient numbers. These have re-
cently been reviewed by Hassan et al. [16]. We have therefore
initiated an observational multi-centre international study, the
‘Peridialysis’ study, in the Nordic and Baltic countries, in order
to improve our understanding of why and when physicians pre-
scribe dialysis [17].
We hypothesized that SDI is a consequence of multiple fac-
tors such as inadequate pre-dialysis care, deficient organization
on the system- and provider-level and insufficient methods to
determine optimal timing of DI. The aim of this study was
therefore to describe characteristic features of SDI and to iden-
tify risk factors for SDI.
MATERIALS AND METHODS
Fifteen Nephrology departments from seven Nordic and Baltic
countries took part in this observational prospective study of
causes and timing of DI. They were publicly financed. They all
had a well-developed multidisciplinary pre-dialysis care struc-
ture including specialist physicians and nurses; 13/15 centres
also had a dietician and 5/15 a social worker.
The most common method of assessing residual renal func-
tion to guide clinical treatment was estimated glomerular filtra-
tion rate (eGFR) as measured by the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) formula [18]. The centres
followed the European Renal Best Practice (ERBP) guidelines for
the initiation of dialysis [19], i.e. dialysis is to be initiated to treat
clinical uraemic symptoms, unless there are specific life-
threatening biochemical problems such as hyperkalaemia.
Patients
All patients starting chronic dialysis therapy for ESRD at the
participating centres between 1 January 2015 and 31 December
2017 were potentially includable. Five centres joined the study
after 1 January 2015 and had a shorter recruiting period.
Methods
Centres supplied estimates of incidence rates of HD and PD. The
number of nephrology specialists at the centre was noted.
Centre policies concerning dialysis planning, access placement
and DI were registered. Late referral to nephrological care was
defined as <3 months before DI.
The following patient data were registered at DI: age, sex,
height, weight, body mass index (BMI), renal diagnosis and
comorbidity.
Dialysis access at first dialysis was registered. DI was classi-
fied as optimal if:
(i) the vascular access for HD was an arteriovenous fistula
(AVF) or arteriovenous graft (AVG);
(ii) the access for HD was a tunnelled catheter as the patient’s
permanent access; and
(iii) the access was a PD catheter, and PD was started >6 days
after placement.
DI was suboptimal (SDI) if:
(i) the access for HD was a temporary vascular catheter;
(ii) the access for HD was a tunnelled catheter, but a later AVF/
AVG was planned; and
(iii) the access was a PD catheter, and PD was started <6 days
after placement, due to dialysis requirement before the
catheter had completely healed.
As patients undergoing pre-emptive kidney transplantation
were often assessed and treated at other departments, they
were excluded from the study.
Clinical data for this population have previously been pub-
lished [17]. For the purposes of this study, clinical symptoms
were classified as being present or not present and representing
a primary cause or not a primary cause of DI. Life-threatening
conditions were defined as the presence of pulmonary stasis,
dyspnoea, cardiac symptoms, pericarditis, acidosis or hyperka-
laemia and similarly classified.
Patient biochemical data
The following biochemical data prior to or in conjunction with
the first dialysis were registered: blood haemoglobin, plasma
concentrations of urea, creatinine, potassium, hydrogen car-
bonate (bicarbonate), albumin, C-reactive protein (CRP), calcium
and phosphate.
Whenever available, plasma creatinine concentration and
date of measurement were registered at the following time
points: referral to the nephrology department; 6 and 3 months
before DI; information about dialysis (and associated modality
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choice); dialysis access prescription; dialysis access placement;
first dialysis. eGFR was calculated using the CKD-EPI formula
[18]. ‘Rapid eGFR loss’ was defined as a fall in eGFR (DeGFR)
>1 mL/min/1.73 m2/month. A positive DeGFR means a falling
eGFR.
Based on post hoc analysis showing that all variables except
blood haemoglobin and plasma albumin correlated to the in-
verse of eGFR (CRP after logarithmic transformation), we de-
fined the ‘excess’ variable concentration as the difference
between the actual variable concentration and the value that
would be expected from the correlation to eGFR. The ‘excess’
variable concentration was used as a supplementary measure
of biochemical uraemia in addition to eGFR.
The study protocol was approved by the ethical review
boards in centres located in countries where according to the
country’s regulations such perusal was required. The study was
approved by the Swedish Ethical Review Authority (Ref 2017/7).
However, in Denmark, due to the observational non-
interventional design of the study using anonymized patient
data, the study protocol was not considered to be eligible for
ethical review. Informed consent—either written or verbal
depending on the regulations in the different countries—was
obtained from participants in all centres including those in
Denmark with the exception of Lithuania, where patient per-
mission was waived by the ethics board (P2-BE-2-9/2014).
The study is registered with ClinicalTrials.gov, identifier
NCT02488200.
Statistics
Data are presented as mean (standard deviation) for normally
distributed variables, median [interquartile range (IQR)] for non-
normally distributed variables, or as numbers and percentage.
Parametric variables were compared using the Students t-test
and analysis of variance, and non-parametric variables using
the Chi-squared, Mann–Whitney and Kruskal–Wallis tests.
Odds ratios were calculated according to Altman. A probability
level of <0.05 was considered significant. Significant values
were expressed as P< 0.05, P< 0.01 or P< 0.001.
RESULTS
Centre details
A total of 1622 patients were included; 24 patients were ex-
cluded due to lack of basic data (age, sex and initial dialysis ac-
cess) and 14 patients were excluded due to pre-emptive
transplantation. The remaining 1583 patients were included in
this study. The number of included patients was 67 (62–153)/
centre, corresponding to an incidence of 35 (21–65) patients/cen-
tre/year. Included patients represented 81% of the estimated to-
tal incidence of 43 (25–77) patients/centre/year. Three centres
had inclusion <70% of the estimated total incidence. The inci-
dence of included patients varied according to centre size; five
non-university centres reported an included incidence <30 new
ESRD patients/year/centre.
Intervals for out-patient visits varied according to the sever-
ity of renal failure. Average visit intervals in weeks were: stable
chronic kidney disease Stage 3 (CKD 3), 28 6 10; unstable CKD 3,
18 6 5; stable CKD 4, 17 6 4; unstable CKD 4, 10 6 4; stable CKD 5,
8 6 4; and unstable CKD 5, 5 6 3 weeks. eGFR was measured at
every visit.
Four centres recommended starting dialysis information at
an eGFR of 20–25 mL/min/1.73 m2, three at 15–19 mL/min/
1.73 m2 and seven at 10–14 mL/min/1.73 m2, while one centre
did not take eGFR into account. One centre stated that they also
considered the rate of eGFR loss.
AVF placement was recommended at an eGFR of <15 mL/
min/1.73 m2 in eight centres and at eGFR of 10–12 mL/min/
1.73 m2 in one centre. Five centres used eGFR loss rate, and one
centre had no eGFR recommendation for timing of AVF place-
ments. AVF placement was performed at median (IQR) 3.8 (1.6–
10.5) months before DI at an eGFR of 9.9 6 3.8 mL/min/1.73 m2.
Planned PD catheter placements were performed with a median
of 0.9 (0.6–1.6) months before DI at an eGFR of 8.5 6 3.7 mL/min/
1.73 m2.
Five centres (33%) had no official guideline for the warranted
level of eGFR at DI, six (40%) recommended eGFR of 9–14 mL/
min/1.73 m2 and four (27%) centres stated that they accepted
eGFR <9 mL/min/1.73 m2 at DI. However, in nine centres (60%),
uraemic symptoms were the major indication for DI.
Patient characteristics
Clinical patient data for patients with optimal DI and SDI are
shown in Table 1. There was no relationship of SDI to age, sex
or diabetic status. Patients with SDI were characterized by high
comorbidity, particularly cardiovascular, and were less likely to
have polycystic renal disease. About 40.2% had life-threatening
conditions, and these were the primary reason for DI in 19.6%.
SDI was required in 52.5% of patients with life-threatening rea-
sons, and this group comprised 339 (51.1%) patients out of all
664 SDI patients.
The primary causes of SDI according to the treating physi-
cian were: acute progression of chronic uraemia in 236 (35.5% of
all SDI), acute uraemia 138 (20.8%), late referral 81 (12.2%),
delayed planning 69 (10.4%), patient non-concordance 60 (9.0%)
[of whom 18 (2.7%) initially refused of dialysis], access problems
28 (4.2%) and other/not stated reasons 29 (4.4%).
Late referrals
Referral times were available for 1478 patients: 495 (33.5% of all
DI) were referred <12 months before DI and 311 (21.0% of all DI)
were referred late (<3 months before DI). Of the latter, 252
(81.0% of all late referrals; 41.0% of all SDI) underwent SDI.
Dialysis access and access placement
The elapsed time between prescription of dialysis access and
access placement did not seem to have any effect on SDI.
Excluding patients with a very short interval (<2 weeks), there
was no correlation between operational delay, even >3 months
and SDI. The average incidence of SDI for patients with an inter-
val >2 weeks was 16.3%.
Rate of eGFR decline prior to DI
The relationships of optimal DI and SDI to eGFR and DeGFR are
shown in Table 2. For optimal DI patients, DeGFR was constant,
around median 6–7 mL/min/1.73 m2/year during the 6 months
prior to DI, while for SDI patients, it accelerated from 8.9 to
21.9 mL/min/1.73 m2/year. Patients with SDI had a significantly
faster DeGFR during the intervals 6–3 months and 3–0 months
before DI. As a corollary, their eGFR was higher at 6 and
3 months before DI, but their eGFR at dialysis information, ac-
cess prescription, access placement and DI were all lower,
even after excluding patients with late referral. Dialysis infor-
mation to early referral SDI patients was given at median eGFR
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9.8 (7.2–12.2) mL/min/1.73 m2, versus 11.2 (9.1–11.2) for non-SDI,
and access was prescribed at median eGFR 7.4 (5.4–9.3) mL/min/
1.73 m2 versus 8.8 (7.2–10.6) (all P< 0.001).
Biochemistry at DI
Biochemical values at DI are shown in Table 3. After correcting
for eGFR, SDI patients were characterized by lower albumin, cal-
cium, bicarbonate and higher urea, phosphate, CRP and potas-
sium levels.
Risk factors for SDI
Significant risk factors for SDI are shown in Table 4. In addition
to the above-mentioned factors, a subgroup of cachectic
patients (BMI<18 kg/m2) had a higher SDI incidence. These
patients had a higher eGFR at DI than non-cachectic patients
(9.9 6 5.9 versus 7.2 6 3.5 mL/min/1.73 m2; P< 0.001).
In a post hoc analysis of 88 patients, plasma albumin at DI
was found to be highly correlated to plasma albumin 3 months
previously (r¼ 0.87), and the difference small (0.2 6 2.7 g/L).
Using three classification groups (plasma albumin <30, 30–34.9
and >34.9 g/L), there was agreement in 86% of patients. Plasma
albumin at DI, which represented a surrogate measure of
plasma albumin 3 months previously, was a highly significant
predictor of SDI.
The most important factors for predicting SDI were late re-
ferral, patient comorbidity, plasma albumin and DeGFR
(Figure 1). About 100% of 35 late referrals with a registered
DeGFR 6–3 months of >1 mL/min/1.73 m2 experienced SDI. For
all subgroups, eGFR 3 months before DI was higher for SDI com-
pared with optimal DI. For patients with plasma albumin <35 g/
L, median eGFR at this point was 15 (10–24) mL/min/1.73 m2.
Centre factors related to SDI
Excluding late referrals, there was no relationship of SDI to
length of pre-dialysis care. Small centres had a significantly
lower SDI rate; these were all non-university centres. There was
no difference in comorbidity between university and non-
university centres, but more patients were referred late to uni-
versity centres (23.2% versus 7.7%, P< 0.01), and patients at uni-
versity centres had a significantly faster DeGFR 3 months before
DI than patients in non-university centres [10.3 (4.1–22.5) versus
8.0 (2.6–15.0) mL/min/1.73 m2/year; P< 0.01]. There was no rela-
tionship between average centre eGFR at DI and incidence of
SDI. The departmental policies for dialysis information, fistula
placement and DI had no measurable effect on SDI. However,
Table 1. Clinical characteristics of patients with optimal DI and SDI
Variable All Optimal DI SDI
Patients, n (%) 1583 919 (58.1) 664 (41.9)
Age, years 63.8 6 15.3 63.7 6 15.2 64.1 6 15.4
Female sex, % 570 (36.0) 342 (37.2) 228 (34.3)
BMI, kg/m2 26.9 6 6.2 27.1 6 6.3 26.5 6 6.1
BMI excluding Type 2 diabetes mellitus 26.1 6 5.9 26.4 6 5.9 25.8 6 5.8
Late referral,a % 311 (21.0) 59 (6.8)** 252 (41.0)**
Renal diagnosis, n (%)
Glomerulonephritis 284 (17.9) 160 (17.4) 124 (18.7)
Interstitial 185 (11.7) 111 (12.1) 74 (11.1)
Polycystic 106 (6.7) 85 (9.2) 21 (3.2)**
Diabetic 387 (24.4) 233 (25.3) 154 (23.2)
Hypertensive 302 (19.1) 196 (21.3) 106 (16.0)*
Other 178 (11.2) 57 (6.2) 121 (18.2)**
Unknown 141 (8.9) 77 (8.4) 64 (9.6)
Comorbidity
No comorbidity 425 (26.9) 265 (28.8) 160 (24.1)*
AMI 171 (10.8) 86 (9.4) 85 (12.8)*
Heart failure 262 (16.6) 128 (13.9) 134 (20.2)**
Cerebrovascular 189 (11.9) 105 (11.4) 84 (12.7)
Peripheral vascular (%) 191 (12.1) 99 (10.8) 92 (13.9)P ¼ 0.06
Diabetes 549 (34.7) 315 (34.3) 234 (35.2)
Cancer 263 (16.6) 137 (14.9) 126 (19.0)*
Pulmonary 151 (9.5) 83 (9.0) 68 (10.2)
Hepatic 61 (3.8) 27 (2.9) 34 (5.1)*
Previous transplantation 81 (5.1) 51 (5.5) 30 (4.5)
Psychiatric 68 (4.3) 38 (4.1) 30 (4.5)
Clinical symptoms 1546 pts.
Present 1291(83.5) 751 (83.7) 540 (83.7)
Primary DI cause 950 (61.4) 574 (63.8) 376 (58.2)*
Life-threatening, n (%)
Present 621 (40.2) 276 (30.7) 339 (52.5)**
Primary DI cause 303 (19.6) 111 (12.3) 192 (29.7)**
Results stated as numbers (%), mean 6 standard deviation or median (IQR).
aOne hundred and seven patients not stated. AMI, acute myocardial infarction.
*P<0.05 (versus optimal),
**P<0.001.
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patients treated at centres with a lower eGFR target for DI
(<9 mL/min/1.73 m2) started dialysis at a lower eGFR than those
starting dialysis in centres with higher eGFR target (eGFR
7.2 6 3.1 versus 7.9 6 3.6 mL/min/1.73 m2; P< 0.01).
Recommended referral eGFR and average visit intervals were
unrelated to SDI regardless of CKD stage or progression rate.
Indeed, a tendency for higher SDI incidence was seen for
centres with relatively short visit intervals.
Other factors related to SDI
Clinical data were available in 1546 patients and has already
been published [17]. The relationship of presence and character
of clinical symptoms to DI is shown in Table 1. The presence of
life-threatening conditions was higher for all forms of SDI and
was the primary cause of DI in 30% (versus 12% for optimal DI).
DISCUSSION
In our study, SDI accounted for 42% of all DIs, similar to that
reported in several previous studies [1, 2], but lower than the
proportion in a recently published report [20]. The high fre-
quency of SDI at our centres may seem surprising, considering
that 85% of the patients were already known to the
Nephrology departments, and were subject to regular multidis-
ciplinary pre-dialysis care.
This is probably the largest prospective multicentre study
assessing patient and centre factors associated with SDI. A ma-
jor advantage of this study compared with previous studies is
that SDI was clearly defined, based on the use of catheters for
dialysis access, thus permitting a more accurate estimate of SDI
incidence. Furthermore, we distinguished prospectively be-
tween tunnelled catheters as the patient’s optimal access, and
those due to delayed placement of an AVF.
We chose not to use in-patient status as part of the defini-
tion of SDI [1], since in our experience many in-patient DI
patients will have received optimal pre-dialysis care, e.g. a pa-
tient with a functioning AVF, who starts dialysis in connection
with acute pneumonia.
Some stated SDI causes were more or less unavoidable: pa-
tient refusal of starting dialysis, clinical indications necessitat-
ing DI despite acceptable biochemistry and doubts about
reversibility. These comprised, however, only 2.6% of patients.
Patient non-concordance and access problems are potentially
avoidable, but comprised only 4.4% of patients, the main stated
causes being an acute progression of chronic uraemia and
delayed planning as assessed by a review of the notes. The lat-
ter comprised 10% of SDI, suggesting that regular audits of pre-
dialysis treatment in SDI patients could reduce SDI.
A previous review [1] identified the following causes of SDI
despite early referral: acute on CKD; suboptimal nephrology
care, patient induced delays and indecision; barriers to surgical
resources; and lack of dialysis resources to accommodate new
patients. In this study, only the first two factors seemed to have
a substantial effect on SDI incidence. This is in contrast to a pre-
vious study on the subject [21], where patient non-concordance
and surgical delays were major causes of SDI. This may in part
explain the high SDI incidence in that study (56%), emphasizing
that SDI incidence is modifiable.
A major finding in this study was that eGFR per se had no
power to predict SDI. Instead, the most important factors linked
to SDI were late referral, rapid decline of eGFR (DeGFR), high co-
morbidity and hypoalbuminaemia. eGFR was stated as the most
important factor guiding dialysis information timing by most
departments; only one mentioned progression rate. While other
centres will presumably also have delayed information given to
patients with very slow progression rates, the results suggest
that results would be improved if more attention is paid to pro-
gression rate rather than eGFR per se. Presence of cardiovascular
disease, especially heart failure, was important. These findings
are similar to those reported by Arulkumaran et al. in their study
on causes and risk factors for acute DI among 825 consecutive
Table 2. Time intervals, eGFR levels and eGFR progression rates at different time points prior to first dialysis in patients with optimal
DI and SDI
Variable Patients included (n) All patients Optimal DI SDI
Time interval, months
Referral dialysis 1320 29.0 (5.6–59.7) 40.4 (18.5–67.4) 7.5 (0.2–45.8)
Information dialysis 1204 4.0 (0.5–10.1) 6.7 (3.0–14.0) 0.3 (0.0–3.8)
Access prescription dialysis 1124 1.1 (0–2.9) 2.3 (1.2–5.0) 0.0 (0.0–0.3)
Access placement dialysis 939 0.5 (0–1.6) 1.2 (0.7–3.4) 0.0 (0.0–0.0)
eGFR, mL/min/1.73 m2
Referral 1414 20.7 (11.5–32.4) 23.0 (15.0–34.0) 15.9 (7.0–30.4)
6 months prior 1202 12.0 (9.6–16.5) 11.1 (9.2–13.6) 16.7 (11.7–26.2)
3 months prior 1225 10.0 (8.0–13.5) 9.3 (7.6–11.4) 13.5 (9.5–20.6)
Dialysis information 1448 10.1 (7.4–12.8) 10.9 (8.8–13.4) 8.1 (5.4–11.5)
Access prescription 1537 7.9 (6.0–10.0) 8.6 (7.1–10.5) 6.6 (4.7–8.7)
Access placement 1499 7.5 (5.5–9.7) 8.3 (6.7–10.4) 6.2 (4.4–8.1)
First dialysis 1571 6.6 (4.9–8.4) 7.0 (5.5–8.9) 6.0 (4.3–7.9)
DeGFR, mL/min/1.73 m2/year
Referral dialysis 1320 5.3 (2.8–10.7) 4.8 (2.8–7.9) 7.6 (3.1–21.2)
6 months prior dialysis 1194 8.5 (4.1–16.5) 6.5 (3.2–10.9) 16.7 (9.1–35.0)
6–3 months prior 1147 6.9 (1.8–14.6) 6.1 (1.6–11.8) 8.9 (2.7–22.3)
3 months prior dialysis 1219 9.6 (3.8–21.0) 7.0 (2.3–13.4) 21.9 (10.8–54.3)
Information dialysis 1204 5.6 (2.0–12.1) 4.8 (1.9–9.2) 9.5 (2.8–25.7)
Access prescription dialysis 1124 4.3 (0.1 to 12.3) 3.8 (0.3 to 9.2) 10.4 (0.0–37.5)
Access placement dialysis 939 3.9 (0.6 to 12.3) 3.9 (0.5 to 11.1) 0.9 (3.6 to 44.9)
Median values (IQR). All P<0.001. D, rate of change of eGFR. Positive values mean falling eGFR.
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patients initiating dialysis [20]. The relationship of SDI to hypo-
albuminaemia has previously been noted [3], as has the rela-
tionship to heart disease [2, 3, 22]. The latter may well be causal,
since the combination of heart failure and uraemia can lead to
intractable oedema and pulmonary stasis requiring acute
dialysis.
An increased rate of eGFR loss in patients with SDI has
previously been noted [20, 23] and was already apparent in
many of our patients 3 months before DI. The CKD-EPI for-
mula for deriving eGFR may, however, distort the rate of
eGFR loss in CKD Stage 5; further investigation of the validity
of CKD-EPI is warranted. If patients are first referred to
the pre-dialysis clinic once they reach CKD Stage 5
(eGFR<15 mL/min/1.73 m2), half of the patients with plasma
albumin <35 g/L will be referred <3 months before DI, with
consequent high risk of SDI. It is possible that earlier identifi-
cation of patients at risk of rapid progression, allowing early
dialysis information and accelerated preparation for start of
dialysis, would help to reduce the number of patients under-
going SDI.
Table 4. Significant risk factors for SDI results stated as n (%) and odds ratio (95% CI)
Variable Group All patients (n; % of column) SDI (n; % of row) Odds ratio (95% CI)
All patients, n (%) – 1583 667 (42.2)
Centre ESRD incidence <30a 264 (16.7) 54 (20.8) Reference
(n/year) 30–70 474 (30.0) 203 (42.8) 2.91 (2.05–4.13)***
>70 845 (53.4) 407 (48.2) 3.61 (2.60–5.00)***
BMIb<18 kg/m2 – 40 (2.9) 23 (57.5) 1.92 (1.01–3.60)*
Polycystic disease – 106 (6.7) 21 (19.8) 0.32 (0.20–0.52)***
Comorbidity numberc 1 342 (21.6) 160 (46.8) 1.38 (1.08–1.77)**
>1 155 (9.8) 82 (52.9) 1.77 (1.26–2.48)***
Previous myocardial infarction – 171 (10.8) 85 (49.7) 1.42 (1.03–1.95)*
Heart failure – 262 (16.6) 134 (51.2) 1.56 (1.20–2.03)***
Hepatic disease – 61 (3.9) 34 (55.7) 1.78 (1.06–2.98)*
Peripheral atherosclerosis – 191 (12.1) 92 (48.2) 1.37 (0.97–1.78)P¼ 0.06
Late referral (<3 months) – 311 (21.0) 252 (81.0) 9.49 (6.97–12.94)***
Life-threatening problem – 621 (40.2) 345 (55.6) 2.58 (2.09–3.19)***
6–3 months DeGFR>1 mL/min/1.73 m2/month – 349 (30.4) 156 (44.7) 2.26 (1.74–2.94)***
3–0 months DeGFR>1 mL/min/1.73 m2/month – 526 (43.2) 288 (54.8) 6.01 (4.61–7.80)***
Average eGFR at DI<7.0 mL/min/1.73 m2 – 845 (53.9) 413 (48.9) 1.89 (1.54–2.32)***
Albumin, g/L <30 489 (34.5) 288 (58.9) 4.72 (3.59–6.19)***
30–34.9 412 (29.1) 156 (37.9) 2.01 (1.51–2.67)***
>34.9 515 (36.4) 120 (23.3) Reference
aAll non-university.
bType 2 diabetes mellitus excluded.
cSum of four identified significant risk factors.
CI, confidence interval. *P< 0.05 (versus optimal); **P< 0.01; ***P<0.001.
Table 3. Biochemical variables at DI in patients with optimal DI and SDI
Variable Number All Optimal DI SDI
Patients with any value, n 1571 911 657
eGFR, mL/min/1.73 m2a 1571 7.3 (3.6) 7.7 (3.4) 6.6 (3.8)
Haemoglobin, mM 1568 6.4 (1.3) 6.6 (1.1) 6.1 (1.4)
Urea, mM 1538 33.8 (12.3) 30.2 (9.6) 38.7 (13.8)
Potassium, mM 1543 4.53 (0.9) 4.40 (0.7) 4.7 (1.0)
Bicarbonate, mM 1182 21.0 (5.1) 21.9 (4.3) 19.6 (5.8)
Albumin, g/L 1418 32.8 (6.7) 34.6 (5.8) 30.1 (7.0)
CRP, mg/L 1445 10 (3–41) 6 (3–16) 28 (6–80)
Calcium ion, mM 1502 1.14 (0.13) 1.17 (0.11) 1.11 (0.14)
Phosphate, mM 1481 1.98 (0.62) 1.85 (0.52) 2.19 (0.68)
Variable excess compared with expected from eGFRb
Urea, mM 1532 0.0 (11.1) 2.4 (9.1) 3.5 (12.6)
Potassium, mM 1536 0.0 (0.8) 0.08 (0.7) 0.11 (1.0)
Bicarbonate, mM 1178 0.0 (4.8) 0.6 (4.3) 0.9 (5.4)
Log CRP, mg/L 1440 0.0 (1.56) 0.47 (1.36) 0.64 (1.59)
Calcium ion, mM 1495 0.0 (0.13) 0.02 (0.12) 0.03 (0.13)
Phosphate excess, mM 1475 0.0 (0.55) 0.08 (0.47) 0.12 (0.64)
Mean (standard deviation) or median (IQR). All P<0.001.
aFor median values, see Table 2.
bFor method of calculation, see Materials and methods section.
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Delayed access placement after prescription did not seem to
be a factor associated with SDI. This may be due to generally ac-
ceptable access to surgery, but it is also possible that surgical
departments are flexible and are able to perform urgent access
placement in patients at greater risk of DI at the time of access
prescription. While access problems at DI could possibly be
averted by earlier access placement, this was not a common is-
sue. Delayed PD catheter placement is rarely a cause of SDI for
most PD patients since PD can be initiated within 1 month after
placement. On the other hand, too early AVF creation could
FIGURE 1: Relationship of comorbidity, plasma albumin and DeGFR 6–3 months before DI to SDI. (A) Comorbidity and uraemia progression; (B) plasma albumin and
uraemia progression; and (C) comorbidity and plasma albumin. Late referrals are excluded. Results are stated as percentage of patients with SDI.
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potentially be a problem; however, recent studies suggest that
the placement of AVF may, in fact, delay uraemia progression
[24–26].
eGFR was used for measuring renal function in this study,
being the most common method in the participating centres.
However, eGFR is not an accurate method for assessment of re-
nal function in CKD 5. Since these patients often suffer from
muscle wasting, leading to low creatinine production and con-
sequent overestimation of eGFR, eGFR is negatively correlated
to muscle mass in patients with CKD 5 [27]. This may be the ex-
planation for the common observation that mortality after DI is
paradoxically positively correlated to eGFR at DI [27–30]. These
limitations of eGFR could be one explanation as to why eGFR
was of no value in predicting SDI; in our study, cachectic
patients had a raised eGFR as had patients with high comorbid-
ity who have an increased risk of malnutrition. It is possible
that measurements of GFR based on urine collections could be a
better tool to identify patients at risk of SDI. If instead of using
eGFR, the mean of urea and creatinine clearance, measured for
a 24-h urine collection is used, then the correlations of GFR to
muscle mass and mortality disappear [27]. The ERBP guidelines,
therefore, recommend this method [19].
In our study, even after correcting for eGFR, higher levels of
urea, potassium, phosphate and CRP and lower levels of haemo-
globin, bicarbonate and calcium, were associated with SDI. This
suggests that SDI patients were more uraemic than indicated by
eGFR, and that inflammation and acute infections also play a
role. Physicians concentrating on eGFR for DI indication may
miss these biochemical warning signs.
Other risk factors for SDI have previously been described in-
cluding the negative impact of late referrals to nephrological
care [23, 31–34]. In this study, 21% of referrals were late
(<3 months before DI), and 81% of these suffered SDI.
Educational programmes for primary and secondary health
organizations may reduce this figure.
We found no overall difference in duration of pre-dialysis
care between optimal DI and SDI, in opposition to previous find-
ings in the literature [35]. This is perhaps not surprising as this
study suggests that it mainly cares during the 6 months preced-
ing DI that is important for preventing SDI. Attention to the
‘quality’ of pre-dialysis care is important. Integrated multidisci-
plinary care with detailed dialysis information given to patients
is reported to be associated with reduced risk of SDI [23, 31, 35–
38], whereas late dialysis information has been shown to be re-
lated to an increased risk of SDI [23, 31]. Frequent out-patient
visits are especially important [35, 39, 40], and more than five
out-patient visits per year seem warranted as frequent visits
may increase the chance of identifying patients with rapid eGFR
loss, a group with a high incidence of SDI. However, there was
no discernible relationship between official departmental policy
concerning visit intervals and SDI. The explanation may be that
most centres permitted a wide variation in visit timing at the
discretion of the treating physician. In our study, SDI patients
received dialysis information at a lower eGFR (8.1 versus
10.9 mL/min/1.73 m2), and it is possible that many cases of SDI
may have been due to delayed response of physicians—and fail-
ure to take action—to eGFR data showing rapid loss of GFR prior
to dialysis information (Figure 1). While multidisciplinary pre-
dialysis care was routine in the centres involved in this study,
the quality and quantity of this care were not assessed. Nor was
patient–doctor continuity, which has emerged as an important
factor for better planning and lower mortality [41].
Other factors that were associated with an increased inci-
dence of SDI included high age, in accordance with the litera-
ture [3, 22, 31, 35], but this was not a major factor. Cachexia was
a cause of SDI in our study in agreement with other studies [23,
35], as was diabetic nephropathy. SDI was less common among
patients with polycystic kidney disease, as reported previously
[2, 22, 23].
The larger university centres participating in this study had
a higher incidence of SDI. The most probable explanation is dif-
ferences in case mix, since patients starting dialysis at univer-
sity centres were more often referred late and had a higher rate
of eGFR loss than patients at smaller non-university centres.
However, it cannot be excluded that the presence of physicians
undergoing specialist training at university centres was more
prone to start dialysis and this could have contributed to a
higher incidence of SDI.
Official departmental policies did not seem to have had
much effect on physician practice, with the exception that
centres with lower eGFR target for DI started dialysis at a lower
eGFR.
There are several limitations to this study. As in all obser-
vational studies, correlations do not prove causality. As com-
pared with the overall incidence of DI at the participating
centres, an estimated 20% of patients were not included in
the study. These patients were not quantified or characterized
and may have differed from the included population. Whereas
one might hypothesize that the proportion of patients with
SDI was higher among non-included patients, the already
high rate of SDI in the study group suggests that inclusion of
these unreported patients would not have changed the results
substantially. Patients with very slow eGFR loss may not have
reached ESRD, or may have died during the study period, and
will not have been included. The time interval between refer-
ral from the primary sector to first nephrological consultation,
a potentially modifiable cause of late referral, was not
recorded. While most patients were included at or before DI, a
few will have been erroneously classified as having reversible
uraemia and included retrospectively.
While treatment practices in the Nordic/Baltic region were
fairly homogeneous, they may differ from clinical practice in
other parts of the world. In particular, the mean eGFR at the
time of dialysis information was relatively low, particularly
when compared with North America. Similar studies from other
regions with differing treatment practices are warranted.
In summary, SDI accounted for 42% of all DIs among 15 di-
alysis centres in the Nordic countries. Whereas SDI is often
unavoidable, many were due to potentially avoidable causes.
The level of eGFR as such was of no value in identifying
patients at risk of SDI; instead, these patients were character-
ized by late referral, accelerated eGFR loss rate, hypoalbumi-
naemia and high comorbidity. Early identification of these
patients, with subsequent close clinical control and acceler-
ated preparation for dialysis, might be a strategy that could
potentially reduce SDI incidence. Thus, many patients would
probably benefit by earlier referral to a pre-dialysis clinic, e.g.
at eGFR of 20 mL/min/1.73 m2, to address comorbidity and
uraemia progression rate. Studies exploring if early identifica-
tion of potential SDI patients will reduce SDI incidence are
warranted. However, any nephrologist taking care of CKD
patients that transition to ESRD can attest that even though
optimal planning for DI had occurred, subsequent care pro-
cesses and clinical events often waylay even the best-laid
plans, thus contributing to the high incidence of SDI.
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